Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;79(11-12):1879–1883. doi: 10.1038/sj.bjc.6690299

E-cadherin and α-, β- and γ-catenin expression in prostate cancers: correlation with tumour invasion

N Morita 1, H Uemura 1, K Tsumatani 1, M Cho 1, Y Hirao 1, E Okajima 1, N Konishi 2, Y Hiasa 2
PMCID: PMC2362820  PMID: 10206308

Abstract

The E-cadherin–catenin complex plays an important role in establishing and maintaining intercellular connections and morphogenesis and reduced expression of its constituent molecules is associated with invasion and metastasis. In the present study, we examined E-cadherin and α-, β- and γ-catenin levels in tumour tissues obtained by radical prostatectomy in order to investigate the relationship with histopathological tumour invasion. Immunohistochemical findings for 45 prostate cancer specimens demonstrated aberrant expression of each molecule to be associated with dedifferentiation and, in addition, alteration of staining patterns for the three types of catenin was significantly correlated with capsular but not lymphatic or vascular invasion. The data thus suggest that three types of catenin may be useful predictive markers for biological aggressiveness of prostate cancer. © 1999 Cancer Research Campaign

Keywords: E-cadherin, catenins, prostate cancer, immunohistochemistry, tumour invasion

Full Text

The Full Text of this article is available as a PDF (230.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Behrens J., Mareel M. M., Van Roy F. M., Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol. 1989 Jun;108(6):2435–2447. doi: 10.1083/jcb.108.6.2435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Black R. J., Bray F., Ferlay J., Parkin D. M. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer. 1997 Jun;33(7):1075–1107. doi: 10.1016/s0959-8049(96)00492-3. [DOI] [PubMed] [Google Scholar]
  3. Boring C. C., Squires T. S., Tong T. Cancer statistics, 1993. CA Cancer J Clin. 1993 Jan-Feb;43(1):7–26. doi: 10.3322/canjclin.43.1.7. [DOI] [PubMed] [Google Scholar]
  4. Bussemakers M. J., van Moorselaar R. J., Giroldi L. A., Ichikawa T., Isaacs J. T., Takeichi M., Debruyne F. M., Schalken J. A. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res. 1992 May 15;52(10):2916–2922. [PubMed] [Google Scholar]
  5. Fournier G., Latil A., Amet Y., Abalain J. H., Volant A., Mangin P., Floch H. H., Lidereau R. Gene amplifications in advanced-stage human prostate cancer. Urol Res. 1995;22(6):343–347. doi: 10.1007/BF00296872. [DOI] [PubMed] [Google Scholar]
  6. Grayhack J. T., Assimos D. G. Prognostic significance of tumor grade and stage in the patient with carcinoma of the prostate. Prostate. 1983;4(1):13–31. doi: 10.1002/pros.2990040103. [DOI] [PubMed] [Google Scholar]
  7. Hall R. R. Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against. Eur Urol. 1996;29 (Suppl 2):24–26. doi: 10.1159/000473833. [DOI] [PubMed] [Google Scholar]
  8. Hinck L., Näthke I. S., Papkoff J., Nelson W. J. Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J Cell Biol. 1994 Jun;125(6):1327–1340. doi: 10.1083/jcb.125.6.1327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jawhari A., Jordan S., Poole S., Browne P., Pignatelli M., Farthing M. J. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology. 1997 Jan;112(1):46–54. doi: 10.1016/s0016-5085(97)70218-x. [DOI] [PubMed] [Google Scholar]
  10. Kadowaki T., Shiozaki H., Inoue M., Tamura S., Oka H., Doki Y., Iihara K., Matsui S., Iwazawa T., Nagafuchi A. E-cadherin and alpha-catenin expression in human esophageal cancer. Cancer Res. 1994 Jan 1;54(1):291–296. [PubMed] [Google Scholar]
  11. Korinek V., Barker N., Morin P. J., van Wichen D., de Weger R., Kinzler K. W., Vogelstein B., Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science. 1997 Mar 21;275(5307):1784–1787. doi: 10.1126/science.275.5307.1784. [DOI] [PubMed] [Google Scholar]
  12. Kowalczyk A. P., Palka H. L., Luu H. H., Nilles L. A., Anderson J. E., Wheelock M. J., Green K. J. Posttranslational regulation of plakoglobin expression. Influence of the desmosomal cadherins on plakoglobin metabolic stability. J Biol Chem. 1994 Dec 9;269(49):31214–31223. [PubMed] [Google Scholar]
  13. Matsui S., Shiozaki H., Inoue M., Tamura S., Doki Y., Kadowaki T., Iwazawa T., Shimaya K., Nagafuchi A., Tsukita S. Immunohistochemical evaluation of alpha-catenin expression in human gastric cancer. Virchows Arch. 1994;424(4):375–381. doi: 10.1007/BF00190559. [DOI] [PubMed] [Google Scholar]
  14. Morin P. J., Sparks A. B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K. W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997 Mar 21;275(5307):1787–1790. doi: 10.1126/science.275.5307.1787. [DOI] [PubMed] [Google Scholar]
  15. Nagafuchi A., Takeichi M., Tsukita S. The 102 kd cadherin-associated protein: similarity to vinculin and posttranscriptional regulation of expression. Cell. 1991 May 31;65(5):849–857. doi: 10.1016/0092-8674(91)90392-c. [DOI] [PubMed] [Google Scholar]
  16. Nakamura Y. Cleaning up on beta-catenin. Nat Med. 1997 May;3(5):499–500. doi: 10.1038/nm0597-499. [DOI] [PubMed] [Google Scholar]
  17. Ochiai A., Akimoto S., Shimoyama Y., Nagafuchi A., Tsukita S., Hirohashi S. Frequent loss of alpha catenin expression in scirrhous carcinomas with scattered cell growth. Jpn J Cancer Res. 1994 Mar;85(3):266–273. doi: 10.1111/j.1349-7006.1994.tb02092.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ozawa M., Baribault H., Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J. 1989 Jun;8(6):1711–1717. doi: 10.1002/j.1460-2075.1989.tb03563.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pierceall W. E., Woodard A. S., Morrow J. S., Rimm D., Fearon E. R. Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines. Oncogene. 1995 Oct 5;11(7):1319–1326. [PubMed] [Google Scholar]
  20. Pisters L. L., Troncoso P., Zhau H. E., Li W., von Eschenbach A. C., Chung L. W. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol. 1995 Jul;154(1):293–298. [PubMed] [Google Scholar]
  21. Richmond P. J., Karayiannakis A. J., Nagafuchi A., Kaisary A. V., Pignatelli M. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res. 1997 Aug 1;57(15):3189–3193. [PubMed] [Google Scholar]
  22. Rimm D. L., Sinard J. H., Morrow J. S. Reduced alpha-catenin and E-cadherin expression in breast cancer. Lab Invest. 1995 May;72(5):506–512. [PubMed] [Google Scholar]
  23. Shibata T., Ochiai A., Kanai Y., Akimoto S., Gotoh M., Yasui N., Machinami R., Hirohashi S. Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. Oncogene. 1996 Sep 5;13(5):883–889. [PubMed] [Google Scholar]
  24. Shimazui T., Schalken J. A., Giroldi L. A., Jansen C. F., Akaza H., Koiso K., Debruyne F. M., Bringuier P. P. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res. 1996 Sep 15;56(18):4154–4158. [PubMed] [Google Scholar]
  25. Siitonen S. M., Kononen J. T., Helin H. J., Rantala I. S., Holli K. A., Isola J. J. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol. 1996 Apr;105(4):394–402. doi: 10.1093/ajcp/105.4.394. [DOI] [PubMed] [Google Scholar]
  26. Smart C. R. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer. 1997 Nov 1;80(9):1835–1844. doi: 10.1002/(sici)1097-0142(19971101)80:9<1835::aid-cncr23>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  27. Syrigos K. N., Krausz T., Waxman J., Pandha H., Rowlinson-Busza G., Verne J., Epenetos A. A., Pignatelli M. E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. Int J Cancer. 1995 Dec 20;64(6):367–370. doi: 10.1002/ijc.2910640603. [DOI] [PubMed] [Google Scholar]
  28. Umbas R., Isaacs W. B., Bringuier P. P., Schaafsma H. E., Karthaus H. F., Oosterhof G. O., Debruyne F. M., Schalken J. A. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994 Jul 15;54(14):3929–3933. [PubMed] [Google Scholar]
  29. Umbas R., Isaacs W. B., Bringuier P. P., Xue Y., Debruyne F. M., Schalken J. A. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer. 1997 Aug 22;74(4):374–377. doi: 10.1002/(sici)1097-0215(19970822)74:4<374::aid-ijc2>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  30. Vleminckx K., Vakaet L., Jr, Mareel M., Fiers W., van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991 Jul 12;66(1):107–119. doi: 10.1016/0092-8674(91)90143-m. [DOI] [PubMed] [Google Scholar]
  31. von Wasielewski R., Rhein A., Werner M., Scheumann G. F., Dralle H., Pötter E., Brabant G., Georgii A. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res. 1997 Jun 15;57(12):2501–2507. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES